INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $3,318 | +24.7% | 63,688 | +51.5% | 0.00% | 0.0% |
| Q2 2023 | $2,661 | -79.5% | 42,045 | -82.5% | 0.00% | -66.7% |
| Q1 2023 | $12,988 | +29.5% | 239,836 | +26.5% | 0.01% | +50.0% |
| Q4 2022 | $10,031 | -99.7% | 189,529 | +189.6% | 0.00% | +33.3% |
| Q3 2022 | $3,044,000 | +96.5% | 65,439 | +141.0% | 0.00% | +200.0% |
| Q2 2022 | $1,549,000 | -33.1% | 27,153 | -28.2% | 0.00% | -50.0% |
| Q1 2022 | $2,315,000 | -78.5% | 37,832 | -81.6% | 0.00% | 0.0% |
| Q4 2021 | $10,778,000 | +541.2% | 205,940 | +356.6% | 0.00% | +100.0% |
| Q3 2021 | $1,681,000 | +135.4% | 45,103 | +158.2% | 0.00% | – |
| Q2 2021 | $714,000 | -77.7% | 17,471 | -81.5% | 0.00% | -100.0% |
| Q1 2021 | $3,203,000 | -35.7% | 94,365 | -39.8% | 0.00% | -33.3% |
| Q4 2020 | $4,984,000 | +35.8% | 156,730 | +9.5% | 0.00% | +50.0% |
| Q3 2020 | $3,671,000 | +25.0% | 143,116 | +25.1% | 0.00% | 0.0% |
| Q2 2020 | $2,937,000 | +741.5% | 114,422 | +405.8% | 0.00% | – |
| Q1 2020 | $349,000 | -85.7% | 22,621 | -68.3% | 0.00% | -100.0% |
| Q4 2019 | $2,446,000 | +882.3% | 71,298 | +113.9% | 0.00% | – |
| Q3 2019 | $249,000 | -85.8% | 33,330 | -75.4% | 0.00% | – |
| Q2 2019 | $1,756,000 | +164.9% | 135,314 | +148.9% | 0.00% | – |
| Q1 2019 | $663,000 | +68.3% | 54,356 | +56.9% | 0.00% | – |
| Q4 2018 | $394,000 | -64.0% | 34,651 | -31.4% | 0.00% | – |
| Q3 2018 | $1,095,000 | +135.0% | 50,501 | +91.4% | 0.00% | – |
| Q2 2018 | $466,000 | -60.1% | 26,381 | -52.5% | 0.00% | -100.0% |
| Q1 2018 | $1,169,000 | +45.2% | 55,509 | -0.3% | 0.00% | – |
| Q4 2017 | $805,000 | -41.8% | 55,667 | -36.5% | 0.00% | -100.0% |
| Q3 2017 | $1,384,000 | -21.7% | 87,698 | -38.4% | 0.00% | -50.0% |
| Q2 2017 | $1,768,000 | +802.0% | 142,437 | +1078.9% | 0.00% | – |
| Q1 2017 | $196,000 | +355.8% | 12,082 | +323.5% | 0.00% | – |
| Q4 2016 | $43,000 | -99.6% | 2,853 | -99.6% | 0.00% | -100.0% |
| Q3 2016 | $10,254,000 | +166.0% | 672,807 | +577.5% | 0.01% | +120.0% |
| Q2 2016 | $3,855,000 | – | 99,300 | +992900.0% | 0.01% | – |
| Q1 2016 | $0 | -100.0% | 10 | -100.0% | 0.00% | -100.0% |
| Q3 2015 | $10,396,000 | +61052.9% | 259,894 | +48569.3% | 0.01% | – |
| Q2 2015 | $17,000 | -79.3% | 534 | -85.0% | 0.00% | – |
| Q1 2015 | $82,000 | +43.9% | 3,551 | +7.1% | 0.00% | – |
| Q4 2014 | $57,000 | +714.3% | 3,315 | +458.1% | 0.00% | – |
| Q3 2014 | $7,000 | 0.0% | 594 | +45.6% | 0.00% | – |
| Q2 2014 | $7,000 | +250.0% | 408 | +308.0% | 0.00% | – |
| Q1 2014 | $2,000 | – | 100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |